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a b s t r a c t
The PRYSPRY domain of TRIM5α provides speciﬁcity and the capsid recognition motif to retroviral
restriction. Restriction of HIV-1 by rhesus TRIM5α (TRIM5αrh) has been correlated to its ability to bind to
the HIV-1 core, suggesting that capsid binding is required for restriction. This work explores whether the
PRYSPRY domain of TRIM5αrh exhibits an additional function besides binding to the HIV-1 core. Using
our recently described structure of the PRYSPRY domain, we performed an exhaustive structure–function
study of the surface and interior residues of the PRYSPRY domain. Testing retroviral restriction and capsid
binding of an extensive collection of 60 TRIM5αrh PRYSPRY variants revealed that binding is necessary
but not sufﬁcient for restriction. In support of this hypothesis, we showed that some human tripartite
motif proteins bind the HIV-1 capsid but do not restrict HIV-1 infection, such as human TRIM6 and
TRIM34. Overall this work suggested that the PRYSPRY domain serves an unknown function, distinct
from the binding of TRIM5αrh to the HIV-1 core, to block HIV-1 infection.
& 2013 Elsevier Inc. All rights reserved.
Introduction
Several newly discovered proteins that are endogenously
expressed in primates show the ability to dominantly block
retroviral infection and cross-species transmission by interfering
with the early phase of viral replication (Best et al., 1996; Kirmaier
et al., 2010; Sayah et al., 2004; Stremlau et al., 2004). Of particular
interest are members of the tripartite motif (TRIM) family of
proteins. The splicing variant a of TRIM5 from rhesus macaque
(TRIM5αrh) is a 53 kDa cytosolic protein that potently restricts
HIV-1 infection (Stremlau et al., 2004). Expression of TRIM5αrh in
mammalian cells blocks HIV-1 and other retroviruses soon after
viral entry but prior to reverse transcription (Keckesova et al.,
2004; Stremlau et al., 2004). The retroviral capsid protein is the
viral determinant for susceptibility to restriction by TRIM5α
(Owens et al., 2003). Studies on the fate of the HIV-1 capsid in
the cytosol of infected cells have correlated restriction with a
decreased amount of cytosolic particulate capsid (Diaz-Griffero
et al., 2007a; Perron et al., 2007; Stremlau et al., 2006).
TRIM5αrh is composed of four distinct domains: RING, B-box 2,
coiled-coil and B30.2 (SPRY) (Reymond et al., 2001). The RING
domain of TRIM5αrh is an E3 ubiquitin ligase (Diaz-Griffero et al.,
2006a; Kar et al., 2008; Kim et al., 2011; Langelier et al., 2008; Li
et al., 2013; Lienlaf et al., 2011; Maegawa et al., 2010; Pertel et al.,
2011; Yamauchi et al., 2008). The E3-ligase activity of TRIM5α is
correlated to the ability of TRIM5α to block HIV-1 (Lienlaf et al.,
2011). The B-box 2 domain of TRIM5α and other TRIM proteins,
such as TRIM63, self-associates to forming dimeric complexes that
are important for TRIM5α higher-order self-association and con-
tribute to capsid binding avidity; these B-box 2 domain functions
are essential for full and potent restriction of HIV-1 (Diaz-Griffero
et al., 2007b, 2009; Ganser-Pornillos et al., 2011; Javanbakht et al.,
2005; Mrosek et al., 2008; Perez-Caballero et al., 2005). The
coiled-coil domain enables TRIM5αrh dimerization (Kar et al.,
2008; Langelier et al., 2008), which is critical for interaction of
the B30.2 (SPRY) domain with the HIV-1 capsid (Sebastian and
Luban, 2005; Stremlau et al., 2006).
The B30.2 (SPRY) domain provides the capsid recognition motif
that dictates speciﬁcity to retroviral restriction (Nakayama et al.,
2005; Sawyer et al., 2005; Song et al., 2005; Stremlau et al., 2005;
Yap et al., 2005). Restriction of HIV-1 by TRIM5αrh has been
correlated to the ability of TRIM5αrh to bind to the HIV-1 capsid,
suggesting that capsid binding is required for restriction. An
invariant patch on the human TRIM5α (TRIM5αhu) protein has
been described as being required for restriction of N-MLV but
dispensable for capsid binding (Sebastian et al., 2009). By using a
limited number of variants, these experiments showed that
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binding is necessary but not sufﬁcient for restriction of N-MLV by
TRIM5αhu suggesting that the PRYSPRY domain has an additional
function. To explore whether the PRYSPRY domain of TRIM5αrh
exhibits an additional function besides binding to HIV-1 capsid, we
performed structure–function studies using our recently described
structure of the PRYSPRY domain (Biris et al., 2012). Analysis of an
extensive collection of PRYSPRY variants revealed two surface
patches that are dispensable for binding but essential for retroviral
restriction.
Results
Mutagenic analysis of the TRIM5αrh PRYSPRY domain
Using the structure of the TRIM5αrh PRYSPRY domain (Biris
et al., 2012), we generated a collection of variants to test the
hypothesis that the PRYSPRY domain exhibits an additional func-
tion besides binding to the HIV-1 capsid. As shown in Fig. 1, our
mutagenesis studies focused on surface and internal residues of
the TRIM5αrh PRYSPRY domain (Table 1 and Fig. 1). This work
explored most of the charge residues on the surface of the PRYSRY
domain, and in cases where changes to alanine resulted in
interesting phenotypes, we proceeded to change these amino
acids to residues of opposite charge. For simplicity mutations
PQIMY327AAAMA, NFNYC345AAAAA and PQIMY327AAAMA/NFN
YC345AAAAA were called 327AAAMA, 345AAAAA and 327AAA
MA/345AAAAA.
To evaluate expression, we stably transduced dog Cf2Th cells
using retroviral vectors expressing HA-tagged mutant and wild
type TRIM5αrh proteins. Expression was evaluated by Western
blotting using anti-HA antibodies (Figs. 2 and S1). As loading
control, we blotted cellular extracts using anti-GAPDH antibodies.
Most of the variants expressed equally well or better, when
compared with to wild type TRIM5αrh (Fig. 2 and Table 1).
However, we also encountered a number of mutants, including
D318E, Y364A, I391A, Y397A, S415A, F417A and R484A that were
difﬁcult to stably express in Cf2Th cells.
Ability of TRIM5αrh PRYSPRY domain variants to restrict HIV-1
To test the ability of TRIM5αrh PRYSPRY domain variants to
block HIV-1 infection, we challenged Cf2Th cells stably expressing
the different variants with increasing amounts of HIV-1 expressing
GFP (HIV-1-GFP) as a reporter of infection. These experiments
revealed that PRYSPRY domain mutants exhibit a variety of
phenotypes ranging from full to the loss of restriction (Figs. 3
and S2). In Table 1, our PRYSPRY domain variants are ranked
according to their ability to block HIV-1 infection.
Ability of TRIM5αrh PRYSPRY domain variants to bind HIV-1 capsid
To test the ability of PRYSPRY domain variants to interact with
the HIV-1 capsid, we tested the ability of the variants to bind
in vitro assembled HIV-1 CA–NC complexes as previously
described (Lienlaf et al., 2011). As in the restriction experiments,
binding experiments revealed that the ability of PRYSPRY variants
to bind HIV-1 capsid ranged from full binding to complete absence
of binding (Figs. 4 and S3). In Table 2, PRYSPRY domain variants are
ranked according to their ability to bind in vitro assembled HIV-1
CA–NC complexes. Of note, we found some variants, e.g. F417A and
327AAAMA/345AAAAA, that had completely lost the ability to
bind in vitro assembled HIV-1 CA–NC complexes.
Binding of TRIM5αrh to HIV-1 capsid is necessary but not sufﬁcient
for restriction
Previous experiments have demonstrated that binding of
TRIM5αrh to HIV-1 capsid is necessary for restriction (Diaz-
Griffero et al., 2006b; Stremlau et al., 2006). For example,
TRIM5αhu does not bind the HIV-1 capsid, and is impaired in its
ability to restrict HIV-1 (Li et al., 2006). In addition, mutations or
deletions of TRIM5 or TRIMCyp that prevented binding to the HIV-
1 capsid were unable to block HIV-1 infection, suggesting that
binding is necessary for restriction (Diaz-Griffero et al., 2006b;
Javanbakht et al., 2005; Perez-Caballero et al., 2005; Stremlau
et al., 2006). To better understand the relationship between the
ability of TRIM5αrh to bind capsid and restrict HIV-1 infection, we
plotted capsid binding as a function of the restriction abilities of
different PRYSPRY variants. As shown in Fig. 5, the ability of
TRIM5αrh PRYSPRY variants to restrict HIV-1 requires binding;
however, binding by itself is not sufﬁcient for restriction since we
found a collection of variants that showed wild type levels of
binding to the HIV-1 capsid while losing their capacity to restrict
HIV-1. These experiments suggested that the PRYSPRY domain is
necessary for restriction but serves some function in addition to
binding.
Careful analysis of variants that allow binding but lose restric-
tion (binding470% and restrictiono40%) revealed two sets of
residues that form surface patches important for restriction
(Fig. 6): Surface patch 1(SP1) is composed of D318, K319 and
R320 (Fig. 6A); Surface patch 2 (SP2) is composed of N326, P327,
Q328, I329, M330 and Y331 (Fig. 6B). Even though SP1 and SP2 are
located on the surface of the TRIM5αrh PRYSPRY domain structure,
we also found that changes in residues located inside the hydro-
phobic core, such as V405 and P483 depicted as the two black dots
Fig. 1. Structure of the PRYSPRY of TRIM5αrh showing the residues targeted in this
study. The upper structures show the surface of the PRYSPRY domain of TRIM5αrh.
Surface and internal residues targeted for mutagenesis are shown in green and
orange, respectively. The lower structures show a transparent surface revealing the
polypeptide chain of the TRIM5αrh PRYSPRY that similarly labels surface and
internal residues targeted for mutagenesis in green and orange, respectively.
Y. Yang et al. / Virology 448 (2014) 217–228218
Table 1
TRIM5αrh PRYSPRY variants ranked according to restriction ability.
TRIM5αrh
Variant
Present at the
surface
of the structurea
Expression
in Cf2Th cellsb
Restriction
potency HIV7SDc
Mean binding to HIV-1
CA–NC complexes7SDd
Y331A þ Y 133 1.41 90 7.77
H423A þ Y 126 5.65 107.5 6.36
S373R þ Y 124 2.82 95 8.48
K475A þ Y 117.5 2.12 75.5 4.94
K413A þ Y 115 0.11 97 15.55
R484M þ Y 112 5.65 83 0.23
F426A þ Y 109 5.65 100 4.24
A427R þ Y 100.5 3.53 100 5.24
wt Y 100 1.22 100 0.98
F429A þ Y 96.5 7.77 95 2.12
T487R þ Y 96 1.41 81.5 4.94
I430R þ Y 91 7.77 111 0.53
Q409R þ Y 90 12.72 60 7.77
Q393R þ Y 90 5.65 25 0.7
F338A þ Y 88 1.62 90 4.94
E395R þ Y 88 7.77 80 1.41
M330A þ Y 87 1.41 75 5
N394A þ Y 84 5.65 96.3 4.66
Q409A þ Y 83.5 3.53 105 5.65
T424R þ Y 83.5 3.53 30 7.07
N394R þ Y 83 2.82 88.5 6.36
N396A – Y 81.5 4.94 90 5.65
K485A þ Y 81 8.48 97 6.36
K467A þ Y 78.5 4.94 88.5 2.12
T304A þ Y 77 1.41 100 3.44
G407A – Y 77 4.24 88.5 30.4
I376A – Y 76.5 2.12 99.5 4.94
R325A þ Y 76 7.07 125 5.65
S355A þ Y 75 2.82 100 0.67
E317A þ Y 70 3.53 98.75 0.35
K319A þ Y 69 5.65 99 1.41
F340A þ Y 66 5.65 70 3.04
E410A þ Y 66 5.65 108 25.45
I437A þ Y 65.5 6.36 100 0.55
D368A þ Y 65 4.24 97 4.24
V412A þ Y 57.5 3.53 100 0.32
D318A þ Y 55 7.07 76 3.18
D302A þ N 54 5.65 105 5.65
L343A þ Y 52 7.77 92.5 10.6
R484A þ N 50.5 7.77 70 8.88
Y348A þ Y 50 7.07 85 3.53
K400A þ Y 48.5 3.53 99 2.82
R441A þ Y 48 2.82 70 0.8
P334R þ Y 41 4.24 70 5.65
N326A þ Y 40 8.48 77 0.98 SP2
327AAAMA/
345AAAAA
þ Y 38 5.65 3.65 1.9
D318K þ Y 36.5 0.7 95 4.1 SP1
D318R þ Y 25 4.94 85 7.07 SP1
V405A – Y 23.5 4.94 95.5 12.02
327AAAMA þ Y 20 4.24 107 28.58 SP2
345AAAAA þ Y 15.5 0.7 38 4.03
R320A þ Y 15 1.41 86 8.48 SP1
P483A – Y 13.5 3.53 97.86 18.5
DK318AA þ Y 7 5.65 100 1.41 SP1
F417A – N 6 1 5.3 4.66
S415A þ N 4 1.41 ND
Y397A – N 3.66 1.15 ND
D318E þ N 3.3 0.42 ND
Y364A – N 3 0.33 ND
I391A – N 3 0.44 23 3.05
TRIM5αrh PRYSPRY variants that lead to the identiﬁcation of surface patches SP1 and SP2 and shaded in gray, and the particular surface patch is indicated on the right side of
the table.
a Localization of residues on the surface of the TRIM5αrh PRYSPRY structure indicated as follows: “þ” means that the residue is on the surface of the structure; “”
means that the residue is in the interior of the structure.
b Expression of each TRIM5αrh variant was measured by Western blot using anti-HA antibodies and quantiﬁed as described in Materials and methods section. “Y” signiﬁes that
the expression of the variant is equal or higher when compared to the wild type (wt); “N” means that the expression is lower relative when compared to the wt.
c Restriction was measured by infecting cells expressing the indicated TRIM5αrh variants with HIV-1 expressing GFP. After 48 h, the percentage of GFP-positive cells (infected
cells) was determined by ﬂow cytometry. Restriction potency was deﬁned here as the fraction of TRIM5αrh PRYSPRY variant fold-restriction relative to the wild-type's fold-restriction
when 50% of the control cells are infected. Experiments were performed at least three times and standard deviations (SD) are shown.
d Binding to the HIV-1 capsid complexes was determined for each TRIM5αrh variant as described in Materials and methods section. Binding is expressed as the amount of
the TRIM5αrh variant bound to HIV-1 capsid complexes divided by the amount of bound wild-type TRIM5αrh at a similar input level. Experiments were repeated at least three times.
The means and standard deviations (SD) are shown. Note that because the binding ratios are calculated at input levels at which some binding of the mutant TRIM5αrh protein to the
HIV-1 capsid complexes can be detected, these ratios overestimate the relative capsid-binding afﬁnities of the mutant proteins.
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surrounded by color dots in Fig. 5, resulted in variants that
potently bound HIV-1 capsid but did not restrict HIV-1 infection
(Fig. 6C). In addition, we observed that SP1 and SP2 were
conserved in human and some species of monkeys (Fig. 6D).
Altogether these experiments suggested that binding of TRIM5αrh
to the HIV-1 capsid is necessary but not sufﬁcient for restriction,
and that the PRYSPRY domain may serve an additional function.
We also observed two variants that exhibit strong HIV-1
restriction but poor binding to capsids (Q393R and T424R). These
results suggested that these particular variants are compensating
the binding to capsid defect by enhancing the postulated addi-
tional function of the PRYSPRY domain in restriction.
Ability of TRIM5αrh PRYSPRY domain variants to shuttle into
and out of the nucleus
We have previously described the ability TRIM5αrh to shuttle
into and out of the nucleus (Brandariz-Nunez et al., 2013; Diaz-
Griffero et al., 2011). To test whether the restriction inability of
the PRYSPRY domain variants that bind capsid is related to the
shuttling properties of TRIM5αrh, we tested the shuttling ability of
PRYSPRY variants that bind HIV-1 capsid but do not restrict HIV-1
infection. For this purpose, we studied localization of PRYSPRY
domain variants in the presence of leptomycin B (LMB), a speciﬁc
inhibitor of nuclear export (Fornerod et al., 1997; Kudo et al., 1998;
Kuersten et al., 2001; Mohr et al., 2009; Watanabe et al., 1999;
Wolff et al., 1997). As shown in Fig. 7, all the tested PRYSPRY
domain variants, which bind HIV-1 capsid but did not restrict HIV-
1, localized to the nuclear compartment in the presence of LMB. In
parallel, we tested the subcellular localization of VI405KK and
IL376AA mutants, which are known to lose their ability to shuttle
in and out of the nucleus (Brandariz-Nunez et al., 2013; Lukic et al.,
2013). Image quantiﬁcation is shown in Supplementary Fig. S4.
These results indicated that the PRYSPRY domain variants, which
bind HIV-1 capsid but do not restrict infection, have not lost the
ability to shuttle in and out of the nucleus.
Tripartite motif proteins that bind in vitro assembled HIV-1 CA–NC
complexes but do not restrict HIV-1
In this section, we tested the ability of TRIM family members
closely related to TRIM5 to bind in vitro assembled HIV-1 CA–NC
complexes. As shown in Fig. 8A, human TRIM6 and TRIM34 binds
in vitro assembled HIV-1 CA–NC complexes, as previously shown
(Li et al., 2007). In agreement with our ﬁndings that some
TRIM5αrh PRYSPRY variants bind the HIV-1 capsid but do not
restrict HIV-1, human TRIM6 and TRIM34 do not restrict HIV-1
infection (Li et al., 2007; Zhang et al., 2006). Furthermore, we
tested the ability of different monkey TRIM5α proteins to bind
in vitro assembled HIV-1 CA–NC complexes. As shown in Fig. 8B,
TRIM5α proteins that do not restrict HIV-1, such as TRIM5α from
chimpanzee and tamarin, bound in vitro assembled HIV-1 CA–NC
complexes. These results suggested that binding to HIV-1 capsid
could occur in the absence of viral restriction.
Discussion
This work represents a comprehensive structure–function
study of the PRYSPRY domain of TRIM5αrh. Using our recently
described structure of the PRYSPRY domain of TRIM5αrh (Biris
et al., 2012), we studied a collection of variants that covered most
of the surface and core residues of the PRYSPRY domain. These
variants were tested for their ability to block HIV-1 infection and
binding to in vitro assembled HIV-1 CA–NC complexes. Analysis of
60 PRYSPRY domain variants revealed that in vitro binding of
TRIM5αrh variants to HIV-1 capsid does not correlate with HIV-1
restriction. These ﬁndings suggested that binding of TRIM5αrh to
the HIV-1 capsid is necessary but not sufﬁcient for restriction,
implying that the PRYSPRY domain provides a second function.
One possibility is that an intact PRYSPRY domain is required
to bind a cellular cofactor, as it has been suggested previously
to explain the ability of TRIM5αhu to restrict N-MLV infection
(Sebastian et al., 2009).
Fig. 2. Expression of TRIM5αrh PRYSPRY domain variants. Dog Cf2Th cells were transduced with the LPCX vector expressing HA-tagged wild-type and mutant TRIM5αrh
proteins. Stable cell lines were selected with 5 μg/ml of puromycin, and the expression levels of mutant and wild-type TRIM5α proteins were assayed by Western blotting
using anti-HA antibodies. To control for protein loading, samples were Western blotted using anti-GAPDH antibodies. The results of three independent experiments were
similar, and the results of a single experiment are shown.
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Alternatively, an intact PRYSPRY domain structure might be
required to maintain the structural ﬂexibility of the V1 loop. The
ﬂexibility of the V1 loop provides structural plasticity (Biris et al.,
2012), conferring upon the PRYSPRY domain the ability to bind
different epitopes, in agreement with independent ﬁndings sug-
gesting that multiple sites on the capsid are important for
recognition by TRIM5α proteins (Kono et al., 2010; Ohkura et al.,
2011; Ohkura and Stoye, 2013). Therefore, we think that our
PRYSPRY domain variants could be affecting structural plasticity,
something that might not be detectable via an ordinary
binding assay.
This work deﬁnes two important surface patches for restric-
tions SP1 and SP2. SP1 is distal from the V1 loop, which has been
genetically deﬁned as an important determinant for the ability of
TRIM5αrh to restrict HIV-1 (Li et al., 2006; Ohkura et al., 2006;
Song et al., 2005; Stremlau et al., 2005; Yap et al., 2005). By
contrast, SP2 is located near or within the V1 loop itself, support-
ing previous observations that the V1 loop is important for
restriction. We also showed that SP1 and SP2 are conserved in
humans and in monkeys such as African green monkeys, chimps
and orangutans.
Interestingly, we also ﬁnd that changes in residues V405 and
P483, which are located in the interior of the protein, resulted in
variants that could bind the HIV-1 capsid in vitro but did not
restrict HIV-1 infection. As previously mentioned, these variants
might be affecting the surface of the PRYSPRY domain and/or the
ﬂexibility of the V1 loop.
These extensive structure–function studies revealed two
PRYSPRY domain variants that potently restricted HIV-1 but poorly
bound HIV-1 capsid in vitro (Q393R and T424R). One possibility is
that these represent gain of function mutants where the defect of
binding to capsid is compensated by enhancing the unknown
function of the PRYSPRY domain.
One caveat of these studies is that the binding of TRIM5αrh
variants to capsid in vitro might not reﬂect the binding of these
proteins in vivo. One possible approach to measure binding of
Fig. 3. Restriction of HIV-1 infection by TRIM5αrh PRYSPRY variants. Dog Cf2Th cells stably expressing the different TRIM5αrh PRYSPRY variants were challenged with
increasing amounts of HIV-1-GFP. Infection was determined by measuring the number of GFP-positive cells 48 h post-infection using a ﬂow cytometer. The graphs are
organized containing mutants from potent to less potent restriction (top to button). Similar results were obtained in three independent experiments, and the result of one
experiment is shown.
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TRIM5αrh variants to capsid in vivo is the use of Förster resonance
energy transfer (Day and Davidson, 2012; Padilla-Parra and Tra-
mier, 2012). Infection of cells expressing different TRIM5αrh
variants fused to ﬂuorophore A by HIV-1 viruses where the viral
cores contain the capsid protein labeled with ﬂuorophore B will
allow the measurement of energy transfer from ﬂuorophore A to B,
depending on how close ﬂuorophore A is from B. Energy transfer
will be an indication of proximity that could be used as an indirect
measure of binding. To test for speciﬁcity of this in vivo binding
assay, we could measure binding of TRIMCyp to HIV-1 viruses
containing the capsid mutant G89V or perform the binding in the
presence of cyclosporine A, which inhibits the binding of TRIMCyp
to in vitro assembled HIV-1 CA–NC complexes (Diaz-Griffero et al.,
2006b; Stremlau et al., 2006). Even though this is a simple
approach, tagging the HIV-1 capsid with a ﬂuorophore in a
manner that will not disrupt formation of the mature core is
challenging, since the capsid forms the mature HIV-1 core by
forming a higher order structure (Ganser-Pornillos et al., 2008).
Because we had previously demonstrated the ability of
TRIM5αrh to shuttle in and out of the nucleus (Diaz-Griffero
et al., 2011), we tested whether variants that bind HIV-1 capsid
but do not restrict the virus are still able to shuttle in and out of
the nucleus. Our results demonstrated that shuttling is normal for
these variants, suggesting that a different function is lost.
Our extensive mutagenesis supports the hypothesis that binding
to HIV-1 capsid could occur in the absence of restriction. To
corroborate this hypothesis, we also tested binding of TRIM family
members closely related to TRIM5 proteins that do not restrict HIV-1
infection. In agreement, TRIM6 and TRIM34 proteins, which do not
restrict HIV-1 infection, bound HIV-1 capsid in vitro (Li et al., 2007;
Zhang et al., 2006). Similarly, TRIM5α proteins from chimpanzee and
tamarin that do not restrict HIV-1 infection bound HIV-1 capsid
in vitro. Overall this work supports the notion that HIV-1 restriction
by TRIM5αrh requires capsid binding and a function provided by the
PRYSPRY domain. Future experiments will attempt to elucidate this
additional function required for restriction.
Materials and methods
Creation of cells stably expressing TRIM5α variants
Retroviral vectors encoding wild type or mutant rhesus mon-
key TRIM5αrh proteins were created using the pLPCX vector. The
Fig. 4. Binding of TRIM5αrh PRYSPRY variants to in vitro assembled HIV-1 capsid–nucleocapsid complexes. Human 293T cells were transfected with plasmids expressing the
indicated wild-type and mutant HA-tagged TRIM5αrh proteins. Forty-eight hours after transfection, cells were lysed. The lysates were incubated at room temperature for 1 h
together with in vitro assembled HIV-1 CA–NC complexes. The mixtures were applied to a 70% sucrose cushion and centrifuged. INPUT represents the lysates analyzed by
Western blotting before being applied to the 70% cushion. The input mixtures were Western blotted using anti-HA antibodies. Similarly, the pellets from the 70% cushion,
which represents the BOUND fraction,were analyzed by Western blotting using anti-HA and anti-p24 antibodies. The results of three independent experiments were similar;
the result of a single experiment is shown.
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Table 2
TRIM5αrh PRYSPRY variants ranked according to capsid binding ability.
TRIM5αrh
variant
Present at the
surface
of the structurea
Expression
in Cf2Th cellsb
Restriction
potency HIV7SDc
Mean binding to
HIV-1 CA–NC complexes7SDd
R325A þ Y 76 7.07 125 5.65
I430R þ Y 91 7.77 111 0.53
E410A þ Y 66 5.65 108 25.45
H423A þ Y 126 5.65 107.5 6.36
327AAAMA þ Y 20 4.24 107 28.58 SP2
Q409A þ Y 83.5 3.53 105 5.65
D302A þ N 54 5.65 105 5.65
F426A þ Y 109 5.65 100 4.24
A427R þ Y 100.5 3.53 100 5.24
wt Y 100 1.22 100 0.98
T304A þ Y 77 1.41 100 3.44
S355A þ Y 75 2.82 100 0.67
I437A þ Y 65.5 6.36 100 0.55
V412A þ Y 57.5 3.53 100 0.32
DK318AA þ Y 7 5.65 100 1.41 SP1
I376A – Y 76.5 2.12 99.5 4.94
K319A þ Y 69 5.65 99 1.41
K400A þ Y 48.5 3.53 99 2.82
E317A þ Y 70 3.53 98.75 0.35
P483A – Y 13.5 3.53 97.86 18.5
K413A þ Y 115 0.11 97 15.55
K485A þ Y 81 8.48 97 6.36
D368A þ Y 65 4.24 97 4.24
N394A þ Y 84 5.65 96.3 4.66
V405A – Y 23.5 4.94 95.5 12.02
S373R þ Y 124 2.82 95 8.48
F429A þ Y 96.5 7.77 95 2.12
D318K þ Y 36.5 0.7 95 4.1 SP1
L343A þ Y 52 7.77 92.5 10.6
Y331A þ Y 133 1.41 90 7.77
F338A þ Y 88 1.62 90 4.94
N396A – Y 81.5 4.94 90 5.65
N394R þ Y 83 2.82 88.5 6.36
K467A þ Y 78.5 4.94 88.5 2.12
G407A – Y 77 4.24 88.5 30.4
R320A þ Y 15 1.41 86 8.48 SP1
Y348A þ Y 50 7.07 85 3.53
D318R þ Y 25 4.94 85 7.07 SP1
R484M þ Y 112 5.65 83 0.23
T487R þ Y 96 1.41 81.5 4.94
E395R þ Y 88 7.77 80 1.41
N326A þ Y 40 8.48 77 0.98 SP2
D318A þ Y 55 7.07 76 3.18
K475A þ Y 117.5 2.12 75.5 4.94
M330A þ Y 87 1.41 75 5
F340A þ Y 66 5.65 70 3.04
R484A þ N 50.5 7.77 70 8.88
R441A þ Y 48 2.82 70 0.8
P334R þ Y 41 4.24 70 5.65
Q409R þ Y 90 12.72 60 7.77
345AAAAA þ Y 15.5 0.7 38 4.03
T424R þ Y 83.5 3.53 30 7.07
Q393R þ Y 90 5.65 25 0.7
I391A – N 3 0.44 23 3.05
F417A – N 6 1 5.3 4.66
327AAAMA/
345AAAAA
þ Y 38 5.65 3.65 1.9
S415A þ N 4 1.41 ND
Y397A – N 3.66 1.15 ND
D318E þ N 3.3 0.42 ND
Y364A – N 3 0.33 ND
TRIM5αrh PRYSPRY variants that lead to the identiﬁcation of surface patches SP1 and SP2 are shaded in gray, and the particular surface patch is indicated on the right side of
the table.
a Localization of residues on the surface of the TRIM5αrh PRYSPRY structure indicated as follows: “þ” means that the residue is on the surface of the structure; “”
means that the residue is in the interior of the structure.
b Expression of each TRIM5αrh variant was measured by Western blot using anti-HA antibodies as described in Materials and methods section. “Y” signiﬁes that the
expression of the variant is equal or higher when compared to the wild type (wt); “N” means that the expression is lower when compared to the wt.
c Restriction was measured by infecting cells expressing the indicated TRIM5αrh variants with HIV-1 expressing GFP. After 48 h, the percentage of GFP-positive cells
(infected cells) was determined by ﬂow cytometry. Restriction potency was deﬁned as the fraction of TRIM5αrh PRYSPRY variant fold-restriction relative to the wild-type's
fold-restriction when 50% of the control cells are infected. Experiments were performed at least three times and standard deviations (SD) are shown.
d Binding to the HIV-1 capsid complexes was determined for each TRIM5αrh variant as described in Materials and methods section. Binding is expressed as the amount of
the TRIM5αrh variant bound to HIV-1 capsid complexes divided by the amount of bound wild-type TRIM5αrh at a similar input level. Experiments were repeated at least
three times. The means and standard deviations (SD) are shown. Note that because the binding ratios are calculated at input levels at which some binding of the mutant
TRIM5αrh protein to the HIV-1 capsid complexes can be detected, these ratios overestimate the relative capsid-binding afﬁnities of the mutant proteins.
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TRIM5αrh proteins contained an inﬂuenza hemagglutinin (HA)
epitope tag at the C terminus. Recombinant viruses were produced
in 293T cells by cotransfecting the pLPCX plasmids with the
pVPack-GP and pVPack-VSV-G packaging plasmids (Stratagene).
The pVPack-VSV-G plasmid encodes the vesicular stomatitis virus
(VSV) G envelope glycoprotein, allowing efﬁcient entry into a wide
range of vertebrate cells. Cf2Th canine thymocytes were trans-
duced and selected in 5 μg/ml puromycin (Sigma).
Protein analysis
Cellular proteins were extracted with radioimmunoprecipita-
tion assay (RIPA) buffer (10 mM Tris, pH 7.4; 100 mM NaCl; 1%
sodium deoxycholate; 0.1% sodium dodecyl sulfate [SDS]; 1% NP-
40; 2 mg/ml aprotinin; 2 mg/ml leupeptin; 1 mg/ml pepstatin A;
100 mg/ml phenylmethylsulfonyl ﬂuoride). Lysates were analyzed
by SDS-PAGE (10% acrylamide), followed by blotting onto nitro-
cellulose membranes (Amersham Pharmacia Biotech). Protein
detection by Western blotting utilized monoclonal antibodies
directed against the HA epitope tags (Roche), FLAG epitope tags
Fig. 6. TRIM5αrh PRYSPRY domain residues that are important for restriction but dispensable for binding to HIV-1 capsid. (A) The surface patch 1 (SP1), composed of D318,
K319 and R320, is shown in red. (B) The surface patch 2 (SP2), composed of N326, P327, Q328, I329, M330 and Y331, is shown in yellow. (C) The polypeptide chain of the
TRIM5αrh PRYSPRY domain showing the internal residues V405 and P483 in orange. In addition the structure shows SP1 and SP2 in red and yellow, respectively. (D) The
conservation of SP1 and SP2 is shown in human and different species of primates such as rhesus macaques (rhesus m), African green monkey pyg [agm (pyg)], African green
monkey Tantalus [agm (tan)], orangutan, chimpanzee, spider monkey, tamarin monkey and squirrel monkey. The number for the rhesus macaque protein sequence is shown.
Fig. 5. Binding of TRIM5αrh to HIV-1 capsid is necessary but not sufﬁcient for
restriction. The relative binding of the different TRIM5αrh PRYSPRY domain variants
to in vitro assembled HIV-1 CA–NC complexes was calculated as described in
Table 1. Similarly, the ability of the different TRIM5αrh PRYSPRY domain variants to
restrict HIV-1 was calculated as described in Table 1. The values for relative binding
to HIV-1 CA–NC complexes were plotted as a function of HIV-1 restriction. Dots in
red and yellow a represent TRIM5αrh PRYSPRY domain variants that are located on
the surface patches SP1 and SP2, respectively.
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(Sigma) and monoclonal antibodies to GAPDH (Sigma) directly
conjugated to Alexa Fluor 680. Bands were detected by scanning
blots with the LI-COR Odyssey Imaging System using both 700 and
800 channels, and integrated intensities were determined using
the LI-COR Odyssey band quantitation software with the median
top-bottom background subtraction method.
Infection with viruses expressing green ﬂuorescent protein (GFP)
Recombinant HIV-1 expressing GFP was prepared as described
(Diaz-Griffero et al., 2008). Recombinant viruses were pseudo-
typed with the VSV-G glycoprotein. For infections, 3104 Cf2Th
cells seeded in 24-well plates were incubated at 37 1C with virus
for 24 h. Cells were washed and returned to culture for 48 h, and
then subjected to FACS analysis with a FACScan (Becton Dick-
inson). HIV-1 and N-MLV viral stocks were titrated by serial
dilution on Cf2Th cells to determine the concentration of infec-
tious viruses.
HIV-1 CA–NC expression and puriﬁcation
The HIV-1 CA–NC protein was expressed, puriﬁed and
assembled as previously described (Ganser et al., 1999; Ganser-
Pornillos et al., 2004). The pET11a expression vector (Novagen)
expressing the CA–NC protein of HIV-1 was used to transform BL-
21 (DE3) Escherichia coli. CA–NC expression was induced with
1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) when the cul-
ture reached an optical density of 0.6 at 600 nm. After 4 h of
induction, the cells were harvested and resuspended in 20 mM
Tris–HCl (pH 7.5), 1 μM ZnCl2, 10 mM 2-mercaptoethanol and
protease inhibitors (Roche). Lysis was performed by sonication
and debris was pelleted for 30 min at 35,000g. Nucleic acids were
stripped from the solution by using 0.11 equivalents of 2 M
(NH4)2SO4 and the same volume of 10% polyethylenimine. Nucleic
acids were removed by stirring and centrifugation at 29,500g for
15 min. Protein was recovered by addition of 0.35 equivalents
of saturated (NH4)2SO4. The protein was centrifuged at 9820g
for 15 min and resuspended in 100 mM NaCl, 20 mM Tris–HCl
Fig. 7. Intracellular distribution of TRIM5αrh PRYSPRY domain variants in the presence of leptomycin B. Human HeLa cells expressing the indicated TRIM5αrh variants were
treated with 20 ng/ml of leptomycin B (LMB) or DMSO for 5 h. Treated cells were ﬁxed and immunostained using anti-HA antibodies (green). Nuclei were stained with DAPI
(blue). The results of three independent experiments were similar and a representative ﬁgure is shown. Quantiﬁcation is shown in Fig. S4.
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(pH 7.5), 1 μM ZnCl2 and 10 mM 2-mercaptoethanol. The CA–NC
protein was dialyzed against 50 mM NaCl, 20 mM Tris–HCl (pH
7.5), 1 μM ZnCl2 and 10 mM 2-mercaptoethanol, and stored at
80 1C.
In vitro assembly of CA–NC complexes
HIV-1 CA–NC particles were assembled in vitro by diluting the
CA–NC protein to a concentration of 0.3 mM in 50 mM Tris–HCl
(pH 8.0), 0.5 M NaCl and 2 mg/ml DNA oligo-(TG)50. The mixture
was incubated at 4 1C overnight and centrifuged at 8600g for
5 min. The pellet was resuspended in assembly buffer (50 mM
Tris–HCl (pH 8.0), 0.5 M NaCl) at a ﬁnal protein concentration of
0.15 mM (Ganser et al., 1999; Ganser-Pornillos et al., 2004), and
stored at 4 1C until needed.
Binding of TRIM5αrh variants to HIV-1 capsid complexes
293T cells were transfected with plasmids expressing wild-type
or mutant TRIM5αrh proteins. Forty-eight hours after transfection,
cell lysates were prepared as follows: previously washed cells
were resuspended in hypotonic lysis buffer (10 mM Tris, pH 7.4,
1.5 mM MgCl2, 10 mM KCl, and 0.5 mM DTT). The cell suspension
was frozen and thawed, and incubated on ice for 10 min. After-
wards, the lysate was centrifuged at maximum speed in a
refrigerated Eppendorf micro centrifuge (14,000g) for 5 min.
The supernatant was supplemented with 1/10 volume of 10 PBS
and then used in the binding assay. In some cases, samples
containing the TRIM5αrh variants were diluted with extracts
prepared in parallel from untransfected cells. To test binding,
5 μl of CA–NC particles assembled in vitro were incubated with
200 μl of cell lysate at room temperature for 1 h. A fraction of this
mixture was stored (input). The mixture was spun through a 70%
sucrose cushion (70% sucrose, 1 PBS and 0.5 mM DTT) at
100,000g in an SW55 rotor (Beckman) for 1 h at 4 1C. After
centrifugation, the supernatant was carefully removed and the
pellet resuspended in 1 SDS-PAGE loading buffer (pellet). The
level of TRIM5αrh proteins was determined by Western blotting
with an anti-HA antibody as described above. The level of HIV-1
CA–NC protein in the pellet was assessed by Western blotting with
an anti-p24 CA antibody.
Immunoﬂuorescence microscopy in the presence of leptomycin B
Transfections of cell monolayers were performed using Lipo-
fectamine Plus reagent (Invitrogen) according to the manufac-
turer's instructions. Transfected cells were incubated at 37 1C for
24 h. Cells were treated for 5 h in the presence of leptomycin B
(20 ng/ml) or DMSO for 5 h. Monolayers were washed twice with
PBS and ﬁxed for 15 min with 4% paraformaldehyde in PBS. Fixed
cells were washed twice with PBS, incubated for 4 min in permea-
bilizing buffer (0.5% Triton X-100 in PBS), and then blocked using
PBS containing 2% bovine serum albumin for 1 h at room tem-
perature. Subsequently, cells were incubated for 1 h at room
temperature with primary antibodies in blocking buffer as
described (Brandariz-Nunez et al., 2013). After three washes with
PBS, the cells were incubated for 30 min with secondary anti-
bodies. Cellular nuclei were labeled with 1 mg/ml of DAPI (4',6-
diamidino-2-phenylindole) in PBS. Subsequently, samples were
mounted for ﬂuorescence microscopy using the ProLong Antifade
Kit (Molecular Probes, Eugene, OR). Images were obtained with a
Zeiss Observer Z1 microscope using a 63 objective, and decon-
volution was performed using the software AxioVision V4.8.1.0
(Carl Zeiss Imaging Solutions).
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Fig. 8. Tripartite motif proteins that bind HIV-1 capsid but do not restrict HIV-1
infection. (A) The ability of TRIM6 and TRIM34 to bind in vitro assembled HIV-1
CA–NC complexes was performed, as described in Materials and methods section.
Brieﬂy, lysates containing TRIM6-FLAG or TRIM34-FLAG were incubated at room
temperature for 1 h together with in vitro assembled HIV-1 CA–NC complexes. The
mixtures were applied to a 70% sucrose cushion and centrifuged. INPUT represents
the lysates analyzed by Western blotting before being applied to the 70% cushion.
The input mixtures were Western blotted using anti-HA antibodies. Similarly, the
pellets from the 70% cushion, which represents the BOUND fraction, were analyzed
by Western blotting using anti-HA and anti-p24 antibodies. The results of three
independent experiments were similar; the result of a single experiment is shown.
(B) Similarly, we tested the ability of TRIM5α proteins from the indicated monkeys
to bind in vitro assembled HIV-1 CA–NC complexes. The ability of these proteins to
restrict HIV-1 is indicated in the bottom of the ﬁgure. The results of three
independent experiments were similar and a representative ﬁgure is shown.
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